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ABSTRACT
Background Many diﬀerent brands of primary
care electronic patient record (EPR) software are
available to general practitioners (GPs). Their ability
to support GPs in improving prescribing varies
greatly.
Objective To assess, using a ten-item tool, the
quality of drug information provided by EPR
software to support the appropriateness of pre-
scriptions and to propose a list of quality standards
for this type of application.
Methods The eight EPR programmes most used
in general practice in Italy were assessed by a
multidisciplinary team using the ten-item tool.
The tool evaluated information on single drugs
and drug safety and information on prescription
rules in force.
Results Out of eight EPR programmes assessed,
none scored more than 55% of the maximum
possible score. Two achieved scores higher than
50%, one scored 48%, four ranged from 32% to
39% and one obtained 22%. Information on drug
safety, such as the ability to detect interactions, to
monitor laboratory parameters or to get updated
information on drug safety was particularly limited.
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Introduction
Primary healthcare electronic patient records (EPR)
were introduced years ago with the potential to
improve the quality of care and the appropriateness
of prescriptions, through reducing untoward side
eﬀects related to medications, decreasing testing and
duplication of care, improving the management of
particular conditions (such as multiple chronic dis-
eases) and decreasing medical errors.
Many studies have addressed the role of EPR
systems in health care but much less is known about
the accuracy of these programmes in supporting
prescribing decisions.1,2
In Italy, a large range of EPR programmes is
available to GPs. Their content and ability to support
GPs in improving drug prescription is notwell known,
and decisions can be inﬂuenced by the quality of
information sources upon which they rely.
In the absence of quality standards for EPR software
in Italy, a studywas set upwith the aim of assessing the
quality of drug information needed for appropriate
prescription (e.g. information on adverse events, ability
to generate drug alerts for drug interactions or for
monitoring clinical parameters and availability of
generic drugs, among others) using a ten-item tool.
Another aim was to deﬁne, according to the results of
the study and by consensus among themembers of the
Scientiﬁc Committee, a list of quality standards that
EPR software should implement in order to facilitate
the improvement of prescription decisions in primary
health care.
Methods
The study, funded by the Regione Veneto, was con-
ducted between July 2008 and March 2009, and
involved a multidisciplinary team (MDT) composed
of three GPs experienced in clinical audit and medical
informatics, seven pharmacists and one clinical phar-
macologist.
Before starting the assessment, the MDT stated the
criterion for selecting the EPR software and deﬁned
the quality indicators and the topics to be critically
evaluated.
In order to select EPR systems, use rate by GPs was
set as the criterion. The eight most used EPR systems
in Italy were identiﬁed and selected, having a user rate
of between 1000 and 11 000 users. Suppliers were then
asked to provide a copy of or access to each system.
The issues to be critically assessed by the committee
addressed three main areas:
1 General information on individual drugs – three
items.
2 Information on drug safety – three items.
3 Information on prescription rules in Italy – four
items.
For each of the above areas a list of indicators was
prepared in order to perform a quantitative and
qualitative assessment. The three areas include a total
of ten items (see Table 1).
Each item was used to assess information available
on a variable number of drugs (from 1 to 12).
Drugs were selected to include some of the most
prescribed drugs in primary health care including
None of the eight EPR programmes contained drug
information for patients, but two of them contained
drug advertising.
Conclusions This project highlighted the poor
quality of drug information provided by these EPR
programmes. The ten-item tool seems suitable for
assessing their quality. Based on this analysis, we have
proposed a set of ten quality standards for prescrib-
ing software.
Keywords: computerisedmedical records systems,
electronic prescribing, medical informatics, MeSH,
quality healthcare indicators, software validation
What this paper adds
. The role of electronic patient record (EPR) systems in improving patients’ outcomes has not been
deﬁnitely established; however, no other studies have addressed to what extent this correlates with the
quality of the information contained in such tools.
. The information aboutmedications available in EPR systems hasmany limitations, in particular regarding
drug safety.
. A set of quality standards for EPR systems are proposed in order to strengthen the ability of these tools to
support GPs in treatment decisions.
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Table 1 Software assessment grid
Item Contents assessed Maximum
score
Drugs assessed (number)
1 Summary of
product
characteristics
(SPC)
Presence of the following SPC sections:
1 Name of the medicinal product
2 Qualitative and quantitative composition
3 Pharmaceutical form (1 point)
4.1 Therapeutic indications (1 point)
4.2 Posology and method of
administration (1 point)
4.3 Contraindications (1 point)
4.4 Special warnings and precautions for
use (1 point)
4.5 Interactions with other medicinal
products and other forms of interaction
(1 point)
4.6 Pregnancy and lactation (1 point)
4.7 Eﬀects on ability to drive and use
machines (1 point)
4.8 Undesirable eﬀects (1 point)
4.9 Overdose (1 point)
6.1 List of excipients
6.2 Incompatibilities
6.4 Special precautions for storage
6.6 Special precautions for disposal and
other handling (1 point)
132 aripiprazole; digoxin;
enoxaparin; etoricoxib;
isotretinoin; lithium;
nimesulide; piroxicam;
pregabalin; rosiglitazone;
rosuvastatin; warfarin
(12)
2 Other information
for GPs
Presence and quality of information other
than SPC (1 point)
12 same as item 1
3 Information for
patients
Presence of drug leaﬂet (1 point)
Presence of other information sources for
the patient for each individual drug
(1 point)
16 amiodarone;
chlorthalidone; digoxin;
enoxaparin; isotretinoin;
lithium; simvastatin;
ticlopidine (8)
4 Drug interactions Detection of interaction (1 point)
Description (1 point)
Severity (1 point)
Suggestion to physicians (1 point)
Book references (1 point)
Date of last updating (1 point)
60 amiodarone + warfarin;
carbamazepine +
clarithromycin;
clarithromycin +
simvatastin; digoxin +
hypericum; digoxin +
furosemide; enalapril +
NSAIDs; methotrexate +
NSAIDs; sildenaﬁl +
nitroglycerin; simvastatin
+ fenoﬁbrate; warfarin +
NSAIDs (10 couples)
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some drugs having a narrow therapeutic index (items
1, 2, 3, 6 and 8). Ten pairs of drugs were selected for
item 4, for which risk of interaction is recognised as
‘relevant’ in the scientiﬁc literature. For item 5, drugs
were selected which have been the subject of recent
product safety announcements (PSA), through ‘dear
doctor’ letters (DDLs), produced by the European
Medicines Agency (EMA) or by the Italian Drug Agency
(AIFA). For item 6, selected drugs corresponded to
drugs frequently used in primary health care for which
some laboratory parameters should be monitored.
For item 7 we chose eight of the most used generic
drugs. Item 9 concerns drugs whose prescription and/
or dispensation are limited in Italy, and item 10
considered the drugmost prescribed to control hyper-
cholesterolemia and cardiovascular risk, linked to a
limited prescription (i.e. AIFA 13).
To obtain a quantitative assessment for each item, a
scoring ranging from 0 – ‘no information available’ to
1 – ‘information available’ was used for each drug
considered within each speciﬁc item.
The total score for each item is the sum of the scores
of its individual sub-items, multiplied by the number
of drugs considered in that speciﬁc item. For example,
item 3 (Information for patients) has two sub-items
and eight drugs assessed. The total score is 2 x 8 = 16
and can oscillate between 0 and 16.
Table 1 Continued
Item Contents assessed Maximum
score
Drugs assessed (number)
5 ‘Dear doctor’
letters (DDLs)/
national safety
advice letters
Availability of product safety
announcements (PSAs) most recently
published by EMA (and/or the Italian
Drug Agency AIFA) (1 point)
The DDL is made available at prescription
(1 point)
The SPC is updated, including DDL
information (1 point for 5 drugs)
17 ceftriaxone; ketorolac;
moxiﬂoxacin; piroxicam;
strontium ranelate;
salbutamol (6)
6 Reminder and
follow-up of
clinical data
At ﬁrst prescription a reminder appears
suggesting the prescription of laboratory
testing as indicated in the SPC (1 point)
At subsequent prescription a reminder
appears regarding monitoring of
laboratory testing, as indicated in the SPC
(1 point)
18 amiodarone;
chlorthalidone; digoxin;
enoxaparin; isotretinoin;
lithium; rosuvastatin;
ticlopidine; warfarin (9)
7 List of available
generic drugs
Presence (1 point) and completeness (1
point) with regard to the list published by
AIFA on equivalent drugs for each drug
Presence of a banner in the software (1
point)
24 amlodipine; enalapril;
gabapentin; lansoprazole;
nimesulide; omeprazole;
ramipril; simvastatin (8)
8 Generic
prescription using
INN
Prescription of drugs by their international
non-proprietary name (INN) (1 point)
12 same as item 1
9 Prescribing rules
in force
Presence of limits to drug prescription,
drug reimbursability, conditions of
delivery etc.
14 alendronate; aripiprazole;
clopidogrel; enoxaparin;
epoetin alfa; gabapentin;
omeprazole; rosiglitazone
(8)
10 CV risk card Presence (1 point) and linking (1 point) at
the time of prescription of simvastatin to
cardiovascular risk charts published by ISS
2 simvastatin (1)
TOTAL SCORE 307
Quality assessment of information about medications in primary care EPR systems 113
As the diﬀerent items have diﬀerent scores, a
weighted score was calculated to make the contri-
bution of every item equivalent. To do so, we have
applied the following formulae:
Weighted score per item= (score obtained in the item/
maximum score obtainable for that item)  total
maximum score.
Weighted total score per software = S score per each
item/number of item.
EPR software analysis
To test the indicator system and the procedure for
scoring the diﬀerent items and sub-items, two re-
searchers (raters) performed a pilot assessment on a
system.During follow-upmeetings between thework-
ing group and the two raters, assessment and scoring
procedures were standardised.
In the event of uncertainties or disagreement be-
tween the two raters, the assessment was discussed and
resolved by the Scientiﬁc Committee.
In addition, for every system assessed, a GP for
reference was selected from among the users. Based on
the qualitative and quantitative assessment of each
system, a detailed grid divided into two parts was
designed: a quantitative part for each item and sub-
item (non-weighted score) and a qualitative part with
comments on the results achieved. A total score could
then be obtained for each system.
The scores were reviewed and discussed by the
Scientiﬁc Committee which ﬁnally approved its use,
and deemed that no ethical approval was needed for
this study. The ﬁnal results for each system were then
sent to the software suppliers for their approval or to
include eventual comments.
Results
Out of eight EPR systems assessed, none scored more
than 55% of the maximum score. In only two cases
were scores higher than 50% (52% and 54%)
obtained; one system scored 48%, four ranged from
32% to 39% and one was around 22%.
Table 2 summarises the percentage score obtained
for each item by diﬀerent EPR systems. Figure 1
illustrates the maximum weighted score obtained by
each EPR system.
Table 2 Percentage score obtained for each item (not weighted score)
Item Software (%)
A B C D E F G H
1 SPC 23 24 27 77 74 75 73 76
2 Other information
for GPs
100 100 0 0 100 100 100 100
3 Information for
patients
0 0 0 0 0 0 0 0
4 Drug interactions 13 3 30 0 10 13 15 77
5 Dear doctor letters
(DDLs)
6 0 6 29 18 29 18 24
6 Reminder and follow
up of clinical data
0 0 33 0 0 0 0 0
7 List of available
generic drugs
25 42 46 33 75 50 63 50
8 Prescription by INN 0 100 58 100 0 100 100 100
9 Prescribing rules in
force
50 79 86 71 57 64 100 64
10 CV risk card 0 0 100 50 50 50 50 50
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General information on drugs
Item 1
No software provided all the information contained in
the summary of product characteristics (SPC) of each
medicine. Diﬀerences in the texts were identiﬁed.
In two out of the 12 drugs considered, therapeutic
indications did not coincide with those of the SPC. In
the case of digoxin, indications and dosages diﬀered
from the SPC in all software, and for piroxicam there
were diﬀerences in ﬁve out of eight programmes
assessed. Parts of the text were also found to bemissing
and in some cases the sections under examination did
not appear at all. For example, in the diﬀerent soft-
ware, the contraindication sections were incomplete
for between three and eight drugs. Parts of the texts in
the section on adverse eﬀects had also been deleted or
changed. Some sections of the technical sheet could
not be found in three EPR systems because mono-
graphs were used instead of the SPC. Figure 2 illus-
trates the maximum weighted score obtained on this
item.
Item 2
In six software systems the only information on drugs
available to GPs was for management purposes,
such as price, reimbursability, dispensing rules etc.
Monographs of the SPC were found in most of the
software.
Item 3
None of the software provides drug information for
patients.
Information on drug safety
Item 4
The type of interaction for each pair of drugs is
provided in seven of the software programmes; the
source of this information, however, is only indicated
in three EPR systems. The clinical impact of the
interaction (severity), the evidence it is based on, the
course of action suggested to physicians and the date it
was updated were found only in one software system
(but they were not found for all ten pairs of drugs).
Figure 3 illustrates the maximum weighted score
obtained on this item.
Item 5
Letters sent out to doctors updating safety infor-
mation or indications were termed ‘dear doctor’
letters (DDLs). The DDL is a tool to update the safety
proﬁle and was not captured by any of the EPR
systems. Some DDLs include an SPC update option;
however, SPCwas only updated in two brands of EPR,
and not for all drugs.
Item 6
A prompt to perform laboratory testing (usually in a
banner pop-up window) was only found in one
software system, for just three out of nine drugs
assessed.
Information on prescription rules and
impact on drugs spending
Item 7
All software includes a list of generic drugs, but this list
was not complete, and did not include the entire AIFA
generic drugs list. Only in two systems was the list of
generic drugs made available at prescription.
Figure 1 Software ranking (weighted score)
Figure 2 Final score for Item 1 – summary of product
characteristics (SPC) Figure 3 Final score for Item 4 – drug interactions
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Item 8
In six out of the eight EPR systems assessed it was
possible to prescribe drugs generically, using the inter-
national non-proprietary name (INN).
Item 9
Although limited conditions for prescribing were
reported in all the software, the complete information
was available in only one system. Other limitations
concerning drug distribution were found in only four
of the assessed software systems.
Item 10
Cardiovascular risk charts/calculators did not appear
when the cholesterol lowering statin simvastatin was
prescribed. In only one system did the risk chart appear
during prescription issue.
Two out of the eight programmes contained drug
advertising.
Discussion
The contents assessment of the most widely used EPR
systems in Italy in terms of supporting correct pre-
scription is rather disappointing. None of the systems
assessed achieved 60% of the maximum score. In
varying degrees, all the software under examination
shared commonproblems and, in particular, the inform-
ation contained in the technical sheet was found to be
incomplete. This might be partly due to the fact that
there is no oﬃcial source of summaries of product
characteristics available in Italy. Other shortcomings
might be attributed to suppliers selecting sources in
which the texts are not adequately updated and/or
modiﬁed so that their content is no longer reliable.
Information and updating on drug safety is also
inadequate, particularly concerning the identiﬁcation
of severe interactions or raising the alert on the pos-
sible parameters to be monitored. To be helpful, such
alerts should be selective and based on a quantitative
risk assessment to avoid GPs cancelling or ignoring
them.3 A large consensus on themost important safety
features of EPR systems for GPs, like that proposed in
the UK,4 is greatly needed in Italy. Besides this,
information on the prescription rules currently in
force in Italy is also deﬁcient in the EPR systems
assessed.
Although on thewhole the international rate of EPR
system use is still low5 the potential of these programs to
improve the quality of health care seems promising.
Many studies have demonstrated the positive eﬀect
of these systems on several outcomes, including patient
satisfaction,6–8 but other studies have reported no
consistent association.9,10Diﬀerentmethods of assess-
ment as well as diﬀerences between EPR systems actually
used in primary health care could explain such dis-
crepancies. In Italy, there are many suppliers of EPR
systems but there are no quality standards for such
tools. The contribution of this study is to propose a
tool to assess the quality of EPR systems, in particular
for prescription related outcomes, and the develop-
ment of quality standards required for EPR systems to
eﬀectively support drug prescribing.
A ﬁrst limitation of the study is that the analysis was
undertaken on EPR systems that do not include any
patient records, hence the performance of the tools in
real practice could not be veriﬁed. A second limit-
itation is that no score was assigned to the qualitative
assessment, which could have modiﬁed the ﬁnal score
of EPR systems.
The following quality standards are proposed for
EPR systems which include prescribing:
1 Drug information contents
. full text of SPC essential
. information on drugs other than SPC, possibly
from independent sources
. patient leaﬂet and/or other independent and
patient oriented sources of information
. no advertising of drugs.
2 Drugs safety contents
. database on severe interactions of drugs used
mainly in primary health care. Such information
should include: detection of interaction, descrip-
tion, severity, suggestion to physicians, references
and date of last updating
. communications on drug safety released by
European or national safety bodies should be
exhaustive and linked to the prescription of such
drugs
. there should be a reminder, at the point of
prescription, of the most relevant parameters
to be monitored when using new drugs and for
drugs that have a narrow therapeutic index
. include for each drug the adverse reaction
reporting form making it easier for this to be
completed in the case of any adverse reaction.
3 Prescription rules information
. a complete and updated list of equivalent drugs
marketed in the country (in our case Italy), listed
by indication and dosage
. prompts to prescribe generically, ideally using
the INN
. updated and exhaustive information on all the
prescription rules in force.
Further research is needed to establish how EPR
systems in Italy can improve patients’ safety in clinical
M Font Pous, M Camporese, A Nobili et al116
practice. An international comparison with EPR sys-
tems used in other countries would also be useful in
order to propose other tools and standards to upgrade
EPR systems as well as providing a common assess-
ment method to compare them.
Conclusions
This project has highlighted the low quality of infor-
mation and support functions related to prescription
found in the most widely used software systems in
general medical practice in Italy. The assessment grid
used in this study can be viewed as a suitable tool to
assess the quality of information needed to support
drug prescription. A set of minimum quality stan-
dards for EPR systems has also been proposed.
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